Immune Signature to Predict Trastuzumab Benefit: Potential and Pitfalls

Lignende værker

• Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831
  af: Pogue-Geile, Katherine L, et al.
  Udgivet: (2020)
• Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology)
  af: Kim, S Rim, et al.
  Udgivet: (2018)
• Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial
  af: Pogue-Geile, Katherine L., et al.
  Udgivet: (2015)
• Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31
  af: Pogue-Geile, Katherine L., et al.
  Udgivet: (2013)
• Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial
  af: Gavin, Patrick G., et al.
  Udgivet: (2017)